Celgene Corporation (CELG) : Iguana Healthcare Management reduced its stake in Celgene Corporation by 12.5% during the most recent quarter end. The investment management company now holds a total of 175,000 shares of Celgene Corporation which is valued at $19,843,250 after selling 25,000 shares in Celgene Corporation , the firm said in a disclosure report filed with the SEC on Aug 15, 2016.Celgene Corporation makes up approximately 7.81% of Iguana Healthcare Management’s portfolio.
Other Hedge Funds, Including , Two Sigma Advisers Lp boosted its stake in CELG in the latest quarter, The investment management firm added 79,572 additional shares and now holds a total of 85,486 shares of Celgene Corporation which is valued at $9,693,258. Celgene Corporation makes up approx 0.05% of Two Sigma Advisers Lp’s portfolio.Redmond Asset Management boosted its stake in CELG in the latest quarter, The investment management firm added 314 additional shares and now holds a total of 13,270 shares of Celgene Corporation which is valued at $1,504,685. Celgene Corporation makes up approx 0.72% of Redmond Asset Management’s portfolio.Edmond De Rothschild Holding S.a. boosted its stake in CELG in the latest quarter, The investment management firm added 10,195 additional shares and now holds a total of 254,172 shares of Celgene Corporation which is valued at $28,820,563. Celgene Corporation makes up approx 0.92% of Edmond De Rothschild Holding S.a.’s portfolio.Oaktop Capital Management Ii reduced its stake in CELG by selling 2,997 shares or 0.14% in the most recent quarter. The Hedge Fund company now holds 2,081,359 shares of CELG which is valued at $236,504,823. Celgene Corporation makes up approx 51.18% of Oaktop Capital Management Ii’s portfolio.Advisory Services Network reduced its stake in CELG by selling 1,551 shares or 4.16% in the most recent quarter. The Hedge Fund company now holds 35,693 shares of CELG which is valued at $3,858,770. Celgene Corporation makes up approx 0.85% of Advisory Services Network’s portfolio.
Celgene Corporation closed down -0.37 points or -0.35% at $106.37 with 34,87,171 shares getting traded on Thursday. Post opening the session at $107.04, the shares hit an intraday low of $105.38 and an intraday high of $107.3025 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.
On the company’s financial health, Celgene Corporation reported $1.44 EPS for the quarter, beating the analyst consensus estimate by $ 0.05 according to the earnings call on Jul 28, 2016. Analyst had a consensus of $1.39. The company had revenue of $2754.00 million for the quarter, compared to analysts expectations of $2709.02 million. The company’s revenue was up 20.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.23 EPS.
Many Wall Street Analysts have commented on Celgene Corporation. Stifel Initiated Celgene Corporation on Jul 15, 2016 to “Buy”, Price Target of the shares are set at $138.
Celgene Corporation (Celgene) together with its subsidiaries is an integrated biopharmaceutical company engaged primarily in the discovery development and commercialization of therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. The Companys primary commercial stage products include REVLIMID (lenalidomide) ABRAXANE POMALYST/IMNOVID VIDAZA azacitidine for injection (generic version of VIDAZA) THALOMID (sold as THALOMID or Thalidomide Celgene outside the United States) OTEZLA (apremilast) and ISTODAX (romidepsin). Celgene is involved in research in a range of scientific areas designed to deliver therapies targeting areas including intracellular signaling pathways protein homeostasis and epigenetics in cancer and immune cells immunomodulation in cancer and autoimmune diseases and therapeutic application of cell therapies.